Latest News
-
Rs 14/Share Dividend: Stockbroking Co To Consider Bonus Share, Shares Up 126% In 180-Days -
Varyaa Creations IPO Set To Shine: Boasts Robust GMP Of Rs 100 -
BEL, HAL, Cochin, Mazagon Dock: Why Defence Stocks Are Flying High When Middle East Is In Kaboom? -
FII-Backed Penny Stock Issues New Update On Warrants, Shares Gain 111% In 3-Yrs -
Top 5 Bank Savings Accounts With No Hidden Charges; Check Details? -
150% Gains In 12 Months: This Multibagger Telecom Stock Hits 52-Week High; IIFL Finance Recommends BUY! -
Singapore Orders Recall Of Everest Fish Curry Masala Over Pesticide -
China's Sinking Cities: Researchers Warn Of A Looming Threat, Say Half Of Major Cities Are Drowning -
Inox Wind Secures Repeat 210 MW Order From Hero Future Energies -
100 Grams Of 22K Gold Dearer By Rs 5000 In India: Check Yellow Metal Prices After Latest Rise
Buy This Pharma Stock, Trading 2% Away From 52-Week Low, For 57% Gain: Motilal Oswal
Motilal Oswal has recommended investors to buy small cap Pharmaceuticals sector stock, Gland Pharma Ltd with a target price of Rs 2660 apiece. The current market price of Gland Pharma is Rs 1693 apiece. The company has a market capitalisation of Rs 27,892.45 crore. Check key takeaways below:
1. Gland Pharma Ltd Stock Outlook
The current market price of the stock is Rs 1693 apiece with a 52-week high at Rs 4060 apiece and 52-week low at Rs 1660 apiece, respectively.
2. Gland Pharma Ltd Return
The stock has fallen 6% in last 5-years, 52% in last 1-year, 38% in last 6-months, and 29% in last 3-months.
3. Gland Pharma Ltd Quarterly Results
The pharma company was incorporated in 1978 and declared its latest quarterly results as on September 30, 2022. The consolidated total income was declared at Rs 1110 crore, up 19% from last quarter total income of Rs 931 crore. The company declared net profit after tax at Rs 241 crore in latest quarter.
4. Gland Pharma Ltd About
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets, according to its official website.
Disclaimer
The stock has been picked from the brokerage report of Motilal Oswal. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
